VANCOUVER, Nov. 20 /CNW/ - Protox Therapeutics Inc. (TSX-V: PRX - News), a leader in advancing, targeted toxin therapeutics for the treatment of cancer and other proliferative diseases, announced today that it has received approximately $7.6 million of a potential $7.7 million from the exercise of warrants issued as a result of the two tranches of a unit private placement financing closed on November 4 and 17, 2005. Any remaining warrants relating to this financing have now expired. This brings the current cash position of the Company to just over $12 million.
